Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Testicular Neoplasms 83%
3. Leukemia 58%
4. Antigens 46%
5. Monoclonal Antibodies 29%
6. Antibody-Dependent Cell Cytotoxicity 27%
7. Immunoconjugates 27%
8. auristatin 19%
9. Proteomics 18%
10. Antibodies 16%
11. Research Personnel 14%
12. Male Genitalia 13%
13. SCID Mice 12%
14. Myeloid Cells 10%
15. Hematologic Neoplasms 10%
16. Hematopoietic Stem Cells 10%
17. Phagocytosis 9%
18. Therapeutics 9%
19. Bone Marrow Cells 9%
20. Lead 9%
21. Heterografts 9%
22. In Vitro Techniques 8%
23. Epitopes 8%
24. Membrane Proteins 8%
25. Clone Cells 8%
26. Flow Cytometry 7%
27. Enzyme-Linked Immunosorbent Assay 7%
28. Macrophages 7%
29. Clinical Trials 6%
30. Pediatrics 6%
31. Cell Line 6%
32. Drug Therapy 5%
33. Recurrence 5%